Developer docs
API playgroundTry for free, no card

Search company profiles

Stratipath Medical

Full company profile

uuid0002hmb

Namestring
Stratipath Medical
Legal namestring
Stratipath AB
Websiteurl
stratipath.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI pathology diagnostics, breast cancer prognostics, digital pathology software, histopathology image analysis, precision oncology diagnostics
Industry2 codes
PRIMARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI-based cancer diagnostics software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software as a Service (SaaS) subscription
TypeSubscription Recurring
Description

Access to Stratipath Breast provided as a Software as a Service solution, available via subscription or pay-as-you-use model. Revenue generated through recurring subscription fees from pathology labs and hospitals.

stratipath.com
2Pay-per-use
TypeUsage Based
Description

Alternative consumption-based model allowing healthcare providers to pay per analysis rather than fixed subscription, providing flexibility for varying usage volumes.

stratipath.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1SaaS subscription model for pathology labs and hospitals
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Subscription or pay-as-you-use model available. Cost per analysis significantly lower than molecular assays.

stratipath.com
2Per-analysis pricing for healthcare providers
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Cost per analysis described as a fraction compared to molecular assays. Results delivered within one hour.

stratipath.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Stratipath Breast
Description

First-in-class CE-IVD marked AI solution for prognostic risk profiling of invasive early-stage breast cancer using H&E-stained histopathology images.

stratipath.com
Core offering1 text field

Stratipath develops and sells Stratipath Breast, a CE-IVD marked AI software solution that performs prognostic risk profiling of invasive early-stage breast cancer by analyzing routine H&E-stained histopathology whole-slide images with deep learning. Delivered as a SaaS subscription or pay-per-use, the product is integrated with leading digital pathology platforms (Roche navify, Sectra, Proscia, Paige, PathAI, Visiopharm, Diagnexia) and used by pathology labs, hospitals, and oncology clinics in the EU, UK, and select international markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Hazard Ratio (HR) of 2.76 between high- and low-risk groups in ER+/HER2- patients in multivariable analysis
+4 more records
Product overview1 text field

Stratipath offers an AI-based precision diagnostics platform focused on cancer treatment decisions. The company's primary offering is Stratipath Breast, a first-in-class CE-IVD marked AI solution for prognostic risk profiling of breast cancer. The platform leverages deep learning technologies to analyze routine H&E-stained histopathology images, providing rapid risk stratification (results within one hour) as an alternative to traditional gene expression tests. The solution is delivered as a Software as a Service (SaaS) model, integrated with leading digital pathology platforms including Roche navify, Sectra, Proscia, Paige, Visiopharm, and Diagnexia.

Product and service1 record
1Stratipath Breast
CategoryAI-based cancer diagnostics software
Description

CE-IVD and IVDR CE-marked AI software for prognostic risk profiling of invasive early-stage breast cancer. Analyzes routine H&E-stained histopathology whole-slide images to classify tumors into low- and high-risk categories and to further resolve intermediate-risk (NHG2) cases, supporting oncologists and pathologists in treatment decision-making. Delivered as a SaaS subscription or pay-per-use via Stratipath's customer web portal and integrated with Roche navify, Sectra, Proscia, Paige, PathAI, and Visiopharm digital pathology platforms.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-04
Description

Strategic collaboration to make Stratipath Breast available within PathAI's AISight Dx Image Management System. Expands access to AI-based precision diagnostics through PathAI's global digital pathology network.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-02
Description

Strategic collaboration to advance implementation of AI-powered breast cancer diagnostics. Combines Visiopharm's digital pathology solutions with Stratipath Breast for enhanced diagnostic workflows.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Strategic partnership to bring Stratipath Breast to pathology laboratories, hospitals, and healthcare providers across the UK and Europe. Diagnexia is a global leader in AI-powered digital pathology with state-of-the-art facilities in Oxford and Exeter. Collaboration integrates Stratipath's technology with Diagnexia's digital pathology network.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-13
Description

Unilabs implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran's Hospital. Three-way collaboration marks significant step towards expanding access to advanced breast cancer diagnostics. Capio St Göran's treats more than 600 breast cancer patients annually.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-09
Description

Non-exclusive collaboration where Roche has distribution rights to integrated Stratipath solution. Integration with Roche's navify Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses. Represents significant step forward in breast cancer diagnostics by leveraging Roche's global distribution network.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-02-08
Description

Stratipath is now part of Paige AppLab, enabling integration with Paige's digital pathology platform and expanding market reach.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-12-05
Description

Partnership to help oncologists and pathologists determine most suitable treatment path for more breast cancer patients. Stratipath is part of Proscia's new partner alliance 'Proscia Ready' focused on delivering integrated digital pathology solutions. Proscia is leading provider of digital and computational pathology solutions.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-08-23
Description

Integration with Sectra's digital pathology solution enables Sectra users to use Stratipath Breast within existing digital pathology workflow. Application featured in Sectra Amplifier Marketplace and purchased directly from Stratipath. Sectra is international medical imaging IT company with over 2,000 installations globally.

9Swedish AI Precision Pathology (SwAIPP) Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-25
Description

Consortium consisting of Stratipath, Karolinska Institutet, pathology clinics in Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas, and Helseplan. Funded by Vinnova with SEK 20 million grant to develop and implement AI-based precision diagnostics in cancer care. SwAIPP 2 continuation funded by Vinnova.

stratipath.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Exact Sciences owns Oncotype DX, an established gene expression test for breast cancer recurrence risk that Stratipath Breast is positioned to substitute. While based on a different technology (molecular rather than AI image analysis), it competes for the same adjuvant chemotherapy decision support budget.

TypeDirect peer
Description

Proscia offers a digital and computational pathology platform with AI applications including its own Proscia Ready partner ecosystem (which includes Stratipath). It is a direct competitor and partner in digital pathology AI.

TypeDirect peer
Description

Visiopharm provides AI image analysis and workflow software for pathology, including cancer diagnostics. It is both a partner of Stratipath and a direct competitor in AI-driven pathology decision support.

4Tempus Labs
TypeBroad incumbent
Description

Tempus is a broad AI-driven precision medicine company spanning oncology diagnostics, multi-omics, and clinical trial support. While not focused specifically on pathology image AI, it competes for the same oncology customer budget and adjacent AI diagnostic slots.

TypeDirect peer
Description

Paige builds AI applications for cancer pathology, including FDA-cleared products for prostate and breast cancer detection. Paige is a direct competitor in AI-driven cancer diagnostics and is also a distribution partner of Stratipath through Paige AppLab.

TypeEmerging player
Description

Owkin applies AI to oncology and other therapeutic areas, with both biopharma R&D and diagnostic products. It is an emerging player in AI-driven precision oncology with partial overlap in AI cancer diagnostics.

TypeDirect peer
Description

Sectra is an international medical imaging IT and digital pathology company with over 2,000 installations globally, hosting Stratipath Breast in its Amplifier Marketplace. It is a direct comparable in enterprise digital pathology and a distribution partner.

TypeDirect peer
Description

PathAI develops AI-powered pathology products for cancer diagnosis and biomarker discovery, including the AISight Dx Image Management System with which Stratipath is already integrated. PathAI is both a partner and the most direct comparable in AI pathology for oncology.

TypeDirect peer
Description

Ibex develops AI-powered diagnostic products for cancer pathology, with deployments in pathology labs worldwide. It is a direct peer in AI-based cancer diagnostics and shares the same target customer (pathology labs) and go-to-market motion.

TypeBroad incumbent
Description

Roche operates navify Digital Pathology, the enterprise platform that distributes Stratipath Breast. As a global diagnostics incumbent with its own AI ambitions, Roche is both the largest channel partner and the largest latent competitive threat.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stratipath Medical

AI-based cancer diagnostics softwarestratipath.com

Stratipath Medical firmographics

Firmographics
Name
Stratipath Medical
Legal name
Stratipath AB
Website
https://stratipath.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Stratipath Medical industry classification

Industry
Product category
AI-based cancer diagnostics software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • AI pathology diagnostics
  • Breast cancer prognostics
  • Digital pathology software
  • Histopathology image analysis
  • Precision oncology diagnostics

Where Stratipath Medical is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Stratipath Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software as a Service (SaaS) subscription: Access to Stratipath Breast provided as a Software as a Service solution, available via subscription or pay-as-you-use model. Revenue generated through recurring subscription fees from pathology labs and hospitals.
  2. Pay-per-use: Alternative consumption-based model allowing healthcare providers to pay per analysis rather than fixed subscription, providing flexibility for varying usage volumes.

Pricing tiers

ModelBillingPrice
SubscriptionPay-as-you-goSaaS subscription model for pathology labs and hospitals
Usage-basedPay-as-you-goPer-analysis pricing for healthcare providers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Stratipath Medical product offering

Product offering

Core offering

Stratipath develops and sells Stratipath Breast, a CE-IVD marked AI software solution that performs prognostic risk profiling of invasive early-stage breast cancer by analyzing routine H&E-stained histopathology whole-slide images with deep learning. Delivered as a SaaS subscription or pay-per-use, the product is integrated with leading digital pathology platforms (Roche navify, Sectra, Proscia, Paige, PathAI, Visiopharm, Diagnexia) and used by pathology labs, hospitals, and oncology clinics in the EU, UK, and select international markets.

Product overview

Stratipath offers an AI-based precision diagnostics platform focused on cancer treatment decisions. The company's primary offering is Stratipath Breast, a first-in-class CE-IVD marked AI solution for prognostic risk profiling of breast cancer. The platform leverages deep learning technologies to analyze routine H&E-stained histopathology images, providing rapid risk stratification (results within one hour) as an alternative to traditional gene expression tests. The solution is delivered as a Software as a Service (SaaS) model, integrated with leading digital pathology platforms including Roche navify, Sectra, Proscia, Paige, Visiopharm, and Diagnexia.

Differentiator

Problem solved

Functional benefit

Brands

  • Stratipath Breast: First-in-class CE-IVD marked AI solution for prognostic risk profiling of invasive early-stage breast cancer using H&E-stained histopathology images.

Products and services

  • Stratipath Breast CE-IVD and IVDR CE-marked AI software for prognostic risk profiling of invasive early-stage breast cancer. Analyzes routine H&E-stained histopathology whole-slide images to classify tumors into low- and high-risk categories and to further resolve intermediate-risk (NHG2) cases, supporting oncologists and pathologists in treatment decision-making. Delivered as a SaaS subscription or pay-per-use via Stratipath's customer web portal and integrated with Roche navify, Sectra, Proscia, Paige, PathAI, and Visiopharm digital pathology platforms.

Quantifiable outcome

  • Hazard Ratio (HR) of 2.76 between high- and low-risk groups in ER+/HER2- patients in multivariable analysis
  • +4 more outcomes

Companies that use Stratipath Medical

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Stratipath Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature5 records

Stratipath Medical partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • PathAIcoreTechnology or Integration · 4 September 2025Strategic collaboration to make Stratipath Breast available within PathAI's AISight Dx Image Management System. Expands access to AI-based precision diagnostics through PathAI's global digital pathology network.
  • VisiopharmcoreTechnology or Integration · 2 September 2025Strategic collaboration to advance implementation of AI-powered breast cancer diagnostics. Combines Visiopharm's digital pathology solutions with Stratipath Breast for enhanced diagnostic workflows.
  • DiagnexiacoreChannel Partner/ Reseller/ Distributor · 1 April 2025Strategic partnership to bring Stratipath Breast to pathology laboratories, hospitals, and healthcare providers across the UK and Europe. Diagnexia is a global leader in AI-powered digital pathology with state-of-the-art facilities in Oxford and Exeter. Collaboration integrates Stratipath's technology with Diagnexia's digital pathology network.
  • UnilabscoreChannel Partner/ Reseller/ Distributor · 13 November 2024Unilabs implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran's Hospital. Three-way collaboration marks significant step towards expanding access to advanced breast cancer diagnostics. Capio St Göran's treats more than 600 breast cancer patients annually.
  • RochecoreChannel Partner/ Reseller/ Distributor · 9 September 2024Non-exclusive collaboration where Roche has distribution rights to integrated Stratipath solution. Integration with Roche's navify Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses. Represents significant step forward in breast cancer diagnostics by leveraging Roche's global distribution network.
  • PaigecoreTechnology or Integration · 8 February 2024Stratipath is now part of Paige AppLab, enabling integration with Paige's digital pathology platform and expanding market reach.
  • ProsciacoreTechnology or Integration · 5 December 2023Partnership to help oncologists and pathologists determine most suitable treatment path for more breast cancer patients. Stratipath is part of Proscia's new partner alliance 'Proscia Ready' focused on delivering integrated digital pathology solutions. Proscia is leading provider of digital and computational pathology solutions.
  • SectracoreTechnology or Integration · 23 August 2022Integration with Sectra's digital pathology solution enables Sectra users to use Stratipath Breast within existing digital pathology workflow. Application featured in Sectra Amplifier Marketplace and purchased directly from Stratipath. Sectra is international medical imaging IT company with over 2,000 installations globally.
  • Swedish AI Precision Pathology (SwAIPP) ConsortiumcoreStrategic or Co-development Partner · 25 October 2021Consortium consisting of Stratipath, Karolinska Institutet, pathology clinics in Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas, and Helseplan. Funded by Vinnova with SEK 20 million grant to develop and implement AI-based precision diagnostics in cancer care. SwAIPP 2 continuation funded by Vinnova.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Stratipath Medical competitors and assessment

Company assessment

Others

  • Exact Sciences: Exact Sciences owns Oncotype DX, an established gene expression test for breast cancer recurrence risk that Stratipath Breast is positioned to substitute. While based on a different technology (molecular rather than AI image analysis), it competes for the same adjuvant chemotherapy decision support budget.

Direct peers

  • Proscia: Proscia offers a digital and computational pathology platform with AI applications including its own Proscia Ready partner ecosystem (which includes Stratipath). It is a direct competitor and partner in digital pathology AI.
  • Visiopharm: Visiopharm provides AI image analysis and workflow software for pathology, including cancer diagnostics. It is both a partner of Stratipath and a direct competitor in AI-driven pathology decision support.
  • Paige.AI: Paige builds AI applications for cancer pathology, including FDA-cleared products for prostate and breast cancer detection. Paige is a direct competitor in AI-driven cancer diagnostics and is also a distribution partner of Stratipath through Paige AppLab.
  • Sectra: Sectra is an international medical imaging IT and digital pathology company with over 2,000 installations globally, hosting Stratipath Breast in its Amplifier Marketplace. It is a direct comparable in enterprise digital pathology and a distribution partner.
  • PathAI: PathAI develops AI-powered pathology products for cancer diagnosis and biomarker discovery, including the AISight Dx Image Management System with which Stratipath is already integrated. PathAI is both a partner and the most direct comparable in AI pathology for oncology.
  • Ibex Medical Analytics: Ibex develops AI-powered diagnostic products for cancer pathology, with deployments in pathology labs worldwide. It is a direct peer in AI-based cancer diagnostics and shares the same target customer (pathology labs) and go-to-market motion.

Broad incumbents

  • Tempus Labs: Tempus is a broad AI-driven precision medicine company spanning oncology diagnostics, multi-omics, and clinical trial support. While not focused specifically on pathology image AI, it competes for the same oncology customer budget and adjacent AI diagnostic slots.
  • Roche (Digital Pathology): Roche operates navify Digital Pathology, the enterprise platform that distributes Stratipath Breast. As a global diagnostics incumbent with its own AI ambitions, Roche is both the largest channel partner and the largest latent competitive threat.

Emerging players

  • Owkin: Owkin applies AI to oncology and other therapeutic areas, with both biopharma R&D and diagnostic products. It is an emerging player in AI-driven precision oncology with partial overlap in AI cancer diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Stratipath Medical social profiles

Digital presence

Stratipath Medical compliance and trust

Trust signal

Compliance3 records

Stratipath Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stratipath Medical leadership team

Management profile

Number of profiles

Profiles6 records

Stratipath Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stratipath Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stratipath Medical

What does Stratipath Medical do?

Stratipath develops and sells Stratipath Breast, a CE-IVD marked AI software solution that performs prognostic risk profiling of invasive early-stage breast cancer by analyzing routine H&E-stained histopathology whole-slide images with deep learning. Delivered as a SaaS subscription or pay-per-use, the product is integrated with leading digital pathology platforms (Roche navify, Sectra, Proscia, Paige, PathAI, Visiopharm, Diagnexia) and used by pathology labs, hospitals, and oncology clinics in the EU, UK, and select international markets.

Is Stratipath Medical a public or private company?

Stratipath Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Stratipath Medical founded?

Stratipath Medical was founded in 2019. It employs 11 to 50 people.

Where is Stratipath Medical based?

Stratipath Medical is headquartered in Solna, Sweden, in the Europe region.

How does Stratipath Medical make money?

Two revenue lines are on record. Software as a Service (SaaS) subscription is the primary driver. The others are pay-per-use.

Who are Stratipath Medical's main competitors?

Exact Sciences is listed as an others. Direct peers are Proscia, Visiopharm, Paige.AI, Sectra, PathAI and Ibex Medical Analytics. Broad incumbents are Tempus Labs and Roche (Digital Pathology). Owkin is listed as an emerging player.

Does Stratipath Medical have an API?

No public API is recorded for Stratipath Medical.

What industry is Stratipath Medical in?

Stratipath Medical's product category is AI-based cancer diagnostics software. Its primary akta.pro industry code is HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Med-Tech InsightsPartnership expands access to precision diagnostics in oncologyStratipath and Aiforia announced a strategic partnership to integrate Stratipath Breast into Aiforia's Clinical Platform, giving laboratories access to both companies' breast cancer AI tools. The collaboration aims to expand access to AI-based precision diagnostics in Europe and worldwide, with joint go-to-market initiatives.news.cision.com“It’s not enough to say you save time or money” – Nordic companies on insights from Health3-2-1Nordic healthtech companies participated in a Health3-2-1 workshop led by Elizabeth Jennings, focusing on entering the U.S. healthcare market. They learned that value alone does not guarantee revenue, as reimbursement is driven by volume and multiple parallel systems. Participants plan to refine their value propositions and target specific stakeholders.GlobeNewswirePathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and PrimaaPathAI announced partnerships with Mindpeak, Stratipath, and Primaa to integrate their AI pathology products into its AISight Dx Image Management System. The collaborations expand PathAI's CE-IVD digital pathology ecosystem, offering validated algorithms for biomarker quantification and diagnostic decision support.GlobeNewswirePathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and PrimaaPathAI announced partnerships with Mindpeak, Stratipath, and Primaa to integrate their AI pathology products into its AISight Dx Image Management System. The partnerships expand PathAI's CE-IVD digital pathology ecosystem, offering tools for breast and lung cancer biomarker quantification, prognostic risk profiling, and dermatopathology.PathaiPathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and PrimaaPathAI announced new partnerships with Mindpeak, Stratipath, and Primaa to integrate their AI-powered digital pathology products into the PathAI AISight Dx Image Management System. This expansion allows pathologists in Europe and other regions to access validated CE-IVD-marked algorithms for biomarker quantification and diagnostic decision support directly through the platform.The Globe and MailThe Globe and MailStratipath and Roche announced a non-exclusive collaboration giving Roche distribution rights to Stratipath Breast, an AI-based breast cancer risk stratification tool. The solution integrates with Roche's navify Digital Pathology software, offering faster, cost-effective prognostic insights compared to molecular tests.GlobeNewswireStratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision DiagnosticsStratipath and Roche announced a non-exclusive collaboration giving Roche distribution rights to Stratipath Breast, an AI-based breast cancer risk stratification tool. The integration with Roche's navify Digital Pathology software enables prognostic risk profiling directly from the platform. The collaboration aims to expand access to AI-powered diagnostics for breast cancer patients.Business InsiderStratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision DiagnosticsStratipath and Roche announced a non-exclusive collaboration where Roche will distribute Stratipath Breast, an AI-based breast cancer risk stratification tool. The solution integrates with Roche's navify Digital Pathology software, offering faster, cost-effective prognostic insights compared to molecular tests. The partnership aims to expand access to AI diagnostics for breast cancer patients.GlobeNewswireFirst CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.Stratipath announced its AI software Stratipath Breast is CE-IVD marked, enabling clinical use in the EU. The software analyzes digital histopathology images to stratify intermediate-risk breast cancers into low- and high-risk groups, offering a faster, cheaper alternative to molecular assays. It is not marketed in the USA.